Health Catalyst beats Q2 2024 guidance: revenue $75.9M, Adj. EBITDA $7.5M

Health Catalyst, Inc.

2024-Q2 EPS reported -$0.58 revenue$150,625,000

Total revenue $75.9M (+4% YoY); net loss $13.5M vs $32.6M loss in Q2 2023.
Adjusted EBITDA $7.5M, exceeding guidance midpoint of $6.0M.
Reiterates FY 2024 revenue $304-312M and Adj. EBITDA $24-26M; Q3 rev guidance $74.5-77.5M.
Signed more net new platform subscription clients in 1H 2024 than all of 2023; targeting low-20s for FY.
Announced $225M credit facility with Silver Point Finance and acquisitions of Carevive and Lumeon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.